

ORIGINAL ARTICLE

Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease

ZIA UR RAHMAN¹, IRFAN ALI KHAN¹, QAZI NAJEEB ULLAH AMIN¹, KASHIF ULLAH SHAH¹, FARMAN ULLAH¹, SAMI ULLAH¹

¹MBBS, FCPS Cardiology, Hayatabad Medical Complex Peshawar

Corresponding author: Qazi Najeeb Ullah Amin, Email: qazinajeeb123@yahoo.com

ABSTRACT

Background: It is still difficult to use drug-eluting stents for the revascularization of small arteries. For patients with diabetes, treatment with a drug-covered balloon for de novo lesions in small coronary vessels are an appealing restoration option. The cause of this research ends up to evaluate the efficacy of DCB-simplest angioplasty for treating small-vessel sickness.

Place of study and duration: Conducted at Cardiology department of Hayatabad Medical Complex Peshawar for the duration from Feb 2019 to Feb 2022.

Methods: A fashionable of 1198 patients with small vascular illness treated with DCB-best approach were observed at Hayatabad Medical Complex Peshawar from Feb 2019 to Feb 2022. Patients were classified as each having diabetes or now not having diabetes. Clinical and angiographical follow-up were organise at 12 months. Target lesion failure and non-primary good sized damaging cardiac activities were used as primary outcomes.

Results: Diabetic patients had a greater hazard of intention lesion failure (17.9% vs. 11.4%, $P=0.006$), and the charge of intention lesion revascularization (9.2% vs. 4.5%, $P=0.014$) emerge as moreover considerably unique many of the 2 companies even as analysed independently. Adjusting for exclusive factors did now not reduce the significance of diabetes mellitus as a predictor of every TLF (HR: 2.712, CI: 1.254-5.864, $P=0.011$) and intention lesion revascularization (HR: 3.698, CI: 1.112-12.298, $P=0.033$). However, there had been no vast versions amongst companies for MACE (19% vs. 2.7%, $P=0.120$) or for intention vessel myocardial infarction (0.6% vs. 0.1%, $P=0.110$).

Conclusion: Reductions in TLF and MACE fees had been seen with drug-coated balloon treatment alone. At three hundred and sixty-five days after treatment with DCBs, diabetes is an independent predictor of intention lesion failure and intention lesion revascularization in small coronary arteries. Within a year, we observed no essential variations in MACE some of the corporations.

INTRODUCTION

Every year, 30–50% of all-comers coronary intervention methods are accomplished on human beings with small artery coronary disease, that's a mentioned predictor of awful consequences following PCI [1–4]. Determining the most effective approach for treating coronary disease in tiny vessels is incredibly difficult [5]. Late lumen loss (LLL) is a major limitation of DES therapy in patients with small vessel disease (SVD) [6–8], leading to high expenditures associated with stent failure, restenosis, and repeated revascularization. This really is due to the fact that DES carry behind metallic arches and polymeric framework within the treatment endothelium, both of whom function as acute inflammation stimulation and prevent the endothelium from regenerating its full capabilities and the lumen from expanding to its maximum potential [9, 10]. This expanded LLL is related to the confined capability of the small vessel to address to even small neointimal proliferation after stent implantation. Diabetes mellitus is also a strong predictor of awful consequences after PCI and there is a well-documented link amongst small vessel coronary disease and this condition [14–16]. Drug-coating balloons (DCB) have been superior as a manner to skip the troubles seen with DES, and there is now evidence to indicate they may be a probable opportunity for treating small vessel disease [17]. Patients with diabetes are more likely to collect the drug-blanketed balloon treatment due to the higher occurrence of SVD in this affected character population. To the satisfactory of our knowledge, there are not any statistics available comparing the consequences of DCB in patients with diabetes rather than those without diabetes who have SVD. Given that DCB benefit the recuperation dreams of DES without reproducing its limitations and downsides, it's far dubious whether or not or now no longer the equal style of results is discovered even as DCB are utilized in evaluation to even as DES are used. Thus, the motive of this research is to observe the long-term success costs of patients with and without diabetes who undergo a drug-blanketed balloon-first-class treatment for de novo small channel coronary disease.

MATERIAL AND METHODS

Study Design and Population: We gift the consequences of prospective, single-center, observational studies of DCB as the only

healing alternative for de novo lesion withinside the local small coronary arteries in 1198 sufferers having percutaneous coronary intervention (PCI). The researchers distinct a reference vessel diameter of 2. seventy-five mm or much less as indicative of small vessel disease. Patients had been labeled as both having diabetes or now no longer having diabetes. Patients had been labeled as diabetic in the event that they had fasting plasma glucose tiers extra than 126 mg/dL (7.0 mmol/L) and/or two-hour plasma glucose tiers extra than 2 hundred mg/dL (11.1 mmol/L) at some stage in an oral glucose tolerance test, and/or HbA1c tiers extra than 6.5%. At 365 days post-procedure, or faster, if necessary, sufferers had been visible on the medical institution for follow-up care.

Exclusion Criteria: Restenosis inside the angioplasty, combination therapies of the threat lesion, treating smaller and larger vessel lesions at the same time, treating clot formation inside the implants and gene expression lesions at the same time, renal failure requiring dialysis, a clinical disease to dual anticoagulation, and end-stage renal disease all necessitate the implantation of a troubled asset relief stent.

Study Endpoints and Definition: Target lesion failure (TLF) become the primary purpose of the trial. TLF included revascularization of the purpose lesion due to ischemia, myocardial infarction associated with the purpose vessel, and cardiac mortality related to the purpose vessel. Myocardial infarction and mortality were classified as TLFs if it became unsure whether or not or now no longer or now no longer the purpose vessel become responsible. Major destructive cardiac events (MACE) were the secondary objectives, and they included all-purpose mortality, myocardial infarction, and revascularization of the targeted artery (TVR). To be considered therapeutically indicated, revascularization of a lesion must be accomplished due to stenosis >50% with evidence of clinical or practical ischemia or a return of the clinical condition for which the first operation got undertaken (TLR). Repeat percutaneous coronary intervention of the target lesion (including 10 mm proximal and 10 mm distal to the index device) or bypass surgery on the target vessel was considered necessary due to the presence of recanalization or other complications, and was subsequently labelled as "tolerable late reintervention" (TLR). A heart attack induced by a blood clot is identified as a cause-related or distal myocardial infarction. The following conditions led to a diagnosis of myocardial

infarction: Indicators of myocardial ischemia include: heart biomarker elevation or depression; at least one result beyond the 90th–99th percentile of the normal range. The development of ischemic sensations and/or signs and/or electrocardiogram (ECG) changes suggestive of new ischemia or the creation of pathologic Q waves strongly suggests ischemia, as do imaging findings of abrupt loss of myocardial blood flow or new adjacent wall motion problems. Acute myocardial infarction, sudden cardiac loss of life, alongside unwitnessed loss of life, coronary heart failure, stroke, cardiovascular procedures, cardiovascular haemorrhage, and unique cardiovascular motives of loss of life were all considered to fall under the umbrella of "cardiac loss of life. For our purposes, "all-purpose loss of life" refers to loss of life from any purpose, while "purpose vessel revascularization" refers to the need for brought endovascular or open-coronary coronary heart surgical treatment to by skip a previously treated location of the artery.

Interventions: If patients' treatments and recoveries were managed in accordance with our established criteria, they would be covered. Patients were given aspirin 300 mg orally at least 24 hours prior to the intervention, clopidogrel or ticagrelor at least six hours prior to the technique, and then continued on aspirin 75 mg/day, clopidogrel 75 mg/day, or ticagrelor 90 mg occurrences daily, with the exception of robust patients on continuous dual antiplatelet medication since a favorable period. Patients with acute coronary syndrome were given loading doses of aspirin (300 mg) and either ticagrelor (100 80 mg) or clopidogrel (600 mg) orally upon admission before undergoing surgery. Both clopidogrel and ticagrelor had been available, and the medical doctor might also additionally select whichever one she or her notion might be maximum effective. Prior to percutaneous coronary intervention (PCI), 0.5 to 0.75mg/kg IV bolus of Enoxaparin turned into given to all sufferers. After the DCB turned into implemented, the operator did now no longer hire balloons for post dilation, albeit she or he turned into unfastened to select the manner for lesion education and the balloons to use. All instances of residual stenosis following percutaneous coronary intervention (PCI) that had been visually evaluated to be much less than 30% had been taken into consideration to had been efficaciously handled via way of means of the intervention. For at the least 6 months following the manner, sufferers had been given a DAPT routine which includes seventy-five mg of aspirin each day similarly to both 75 mg of clopidogrel or ninety mg of ticagrelor two times each day.

Device Description: A paclitaxel-covered balloon catheter, turned into used on all the sufferers. A matrix coating of paclitaxel and a hydrophilic spacer is implemented to the balloon floor at a dose of 3g/mm². forty seconds of inflation time is needed for the drug to be launched into the vessel wall, and after that point handiest 4.5% of the drug continues to be at the balloon.

Follow-Up: We carried out a medical follow-up with all sufferers at 12 months (in-individual and cellphone visits) and evaluated their medications, excellent of life, and unfavorable activities with a standardized questionnaire. After a year, or quicker, if necessary, angiographic follow-up appointments had been set up. An unbiased medical committee oversaw all the study's endpoints, and a blinded middle lab tested the accuracy of the angiograms.

Statistical Analysis: The frequencies and probabilities of the occurrences of an express variable are provided, while the suggest and widespread deviation of a non-stop variable are given. In order to evaluate express variables, we used both the 2-tailed Fisher's actual take a look at or the Pearson's chi-squared take a look at, whilst we used the unbiased samples t-take a look at (additionally referred to as the "Student's t-take a look at") to evaluate non-stop variables. Cox proportional risk multivariate evaluation become used to decide the risk ratios (HR) and 95% self-belief durations for capacity predictors of TLF and TLR (CI). Bilateral P 0.05 become taken into consideration statistically substantial.

RESULTS

Patients Baseline Characteristics: Of the 1198 sufferers, 831 had been male and 367 had been female; 430 had been identified with diabetes whilst the last 768 did now no longer have the

condition. Patients with diabetes had been tons older and much more likely to have hypertension, hyperlipidemia, and renal failure than the ones without diabetes.

Baseline Lesions Characteristics: A general of 1351 lesions were treated, with 483 determined withinside the diabetes company and 868 withinside the non-diabetic company. Bifurcation, ostial lesion, thrombosis, and disseminated lesion all took place greater frequently withinside the diabetic company, despite the fact that there were no statistically sizable versions a number of the 2. There turn out to be a statistically sizable increase in the prevalence of persistent complete occlusion, calcified lesions, and longer advise lesion period withinside the nondiabetic company in comparison to the diabetic company.

Procedure Characteristics: Standard artery thickness was comparable in the diabetes and nondiabetic groups (2.5, 0.2 vs. 2.5, 0.8; P=0.366), but so were Operating voltage inflating level and period (59.9, 3.76 s vs. 60.1, 4.93 s; P=0.416 and P=0.474, respectively).

Outcomes: Angiographic follow-up turn out to be completed on 535 (44.6%) of 1198 patients who have been initially enrolled. Comparing the diabetic and nondiabetic companies, Lowest membrane length (MLD) was significantly different in the two groups (1.89 vs. 0.53 vs. 2.039; P=0.07), as were luminal length (LLL) and dichotomous revascularization (4.8% vs. 1.1%; P=0.003). TLF incidence expenses have been notably specific amongst companies, with the diabetic population having a extra incidence (3.9 % vs. 1.4%; P=0.006). TLR expenses have been notably extra withinside the diabetes business enterprise at the same time as TLF components have been analysed independently (2% vs. 0.5 %; P=0.014). Nonetheless, there was no considerable difference many of the companies with respect to myocardial infarction withinside the aim vessel (0.6% vs. 0.1%; P=0.110). Comparing the MACE many of the 2 companies, there have been no statistically considerable versions (4.4% vs. 2.7%; P=0.120).

Target Lesion Revascularization and Target Lesion Failure: An Independent Predictor: After adjusting for different factors, diabetes remained a considerable predictor of each TLF and MACE in our multivariate logistic regression examine for TLF and TLR.

DISCUSSION

Most DCB research on small vessels employed a cutoff component of 2.8 mm for small vessel definition, which is consistent with the recommended optimal exclusion to increase awareness of tiny vessels. The definition of a miniature artery used a comparative vessel length of around 2.7 mm. Studies [18–20] suggest that DCB is as effective as DES in treating small coronary arteries. DCB results in people with diabetes and non-diabetic people with de novo small coronary arteries have not been directly compared to date. As shown by the results of this thorough single-center observational study, individuals with diabetes incurred considerably higher TLF (3.9 % vs. 4 per cent; P=0.006) and TLR (2.0 percent vs. 0.5 percent; P=0.014) expenses. Major cardiovascular events occurred more often in diabetic individuals (4.4% vs. 2.7%; P=0.120). Although there is still a difference, it is no longer statistically significant. After accounting for confounding variables, patients with diabetes still had a greater than average risk of developing TLF (HR: 2.712; CI: 1.254-5.864; P=0.011) and TLR (HR: 3.698; CI: 1.112-12.298; P=0.033). Similar to previous research [21], we observed that DCB had optimal low costs of TLF and MACE inside the tiny vessel. Rates of MACE occasions have been 6.1% withinside the PEPCAD I examine at 12 months, and 7.5% withinside the DCB arm of the BASKET-SMALL 2 trial at 23, 31 months. According to the literature, the 9-month MACE for DCB angioplasty in older sufferers with SVD become 4.2%. Rates of TLF incidents have been 4.3% withinside the RESTORE SVD China Randomized Study. In assessment to those different trials, our fees of TLF (2.3%) and MACE episodes (3.0%) have been drastically decreased. In SVD, the "depart not anything in the back of strategy" is idea to be a contributing aspect to the reducing

MACE fees visible with the usage of drug-covered balloons. Post-system luminal enlargement with DCB-best angioplasty has been reported, and acetylcholine checking out has proven much less intense coronary endothelial disorder and no acute or past due thrombosis 4. We discovered drastically decrease MACE fees withinside the diabetic organization than were visible before. They're become a fashion in the direction of decreased TLR in diabetic folks who took DCB, in accordance to investigate via way of means of Magaly et al. Even in high-chance diabetic individuals, DCB become discovered to have a good-sized development withinside the tiny arteries, as proven via way of means of the BELLO research.

All of the noted research had smaller pattern sizes than our own, which can also additionally provide an explanation for in element why our have a look at observed a decrease MACE prevalence than earlier research. Second, there have been various standards for inclusion; for example, Sinega et al. enrolled a populace of older men and women who, in comparison to the overall populace, are much more likely to show off a bigger share of all of the classical danger elements for MACE. Poor consequences are expected independently via way of means of DCB angioplasty observed via way of means of bailout BMS implantation [22]. In comparison to the aforementioned research, we did now no longer consist of any of the bailout stenting in our evaluation. In addition, we covered simplest tactics wherein the posted guidelines for lesion guidance have been observed, as that is the maximum essential issue in a a success DCB angioplasty [23]. Our findings are steady with the ones of the Jalaluddin experiment, which observed notably better prevalence of TLR (1.4% vs. 0.6%; $P=0.049$) withinside the diabetic institution [24]. These consequences corroborate the metabolic and hematologic modifications visible in humans with diabetes in comparison to the ones withinside the widespread populace. Hypercoagulability, accelerated atherosclerosis progression, endothelial dysfunction, and accelerated platelet aggregation and clotting are all related to diabetes. Diabetic people have a better occurrence of residual plaque throughout the reference phase in comparison to nondiabetic sufferers, and a latest intravascular ultrasonography research observed a correlation among better occurrence of plaque and accelerated danger of part stenosis with DES and BMS. When the usage of DCB, this end result is probably replicated. Diabetic sufferers had a statistically widespread accelerated price of residual stenosis after DCB [25].

In assessment to our findings, Jalaluddin discovered that the diabetes group had a greater incidence of MACE events (4.3% vs. 0.6%; $P=0.000$) and MI (2.6% vs. 0.4%; $P=0.002$). The effect of DCB on the TVR 40 4 have become confirmed to be unaffected through manner of method of diabetes, steady with a meta-assessment through manner of method of Sánchez et al. In our trial, we excluded all bailout stenting and best enrolled patients with a vascular diameter of 2.75 mm or less, therefore the ones contrasting findings may be attributable, as a minimum in element, to the top-notch inclusion standards. Nonetheless, Jalaluddin counted all patients, irrespective of their vascular size. Considering that the risk of restenosis after PCI decreases with increasing vessel size, it is crucial to remember the heterogeneity of the covered trials with respect to vessel size (3 mm, 2.8 mm, and 2.75 mm). The absence of standardized pre-dilatation of lesions in the PICCOLETO trial, as well as variations in follow-up length among the 40+ studies that were recruited to study BMS implantation as a rescue treatment, were among the methodological flaws that were identified.

CONCLUSION

Our information display that during sufferers with de novo small coronary artery disease, the drug-covered balloon on my own led to a reduced occurrence of goal lesion failure and sizeable damaging cardiac events. We determined that the TLF and TLR occasion fees have been extensively more withinside the diabetes populace as compared to the nondiabetic populace. Although there

has been no statistically sizeable distinction among the diabetes and non-diabetic groups, the diabetic organization did have a better normal charge of MACE, TVR, MI, and cardiac mortality. During the 12-month follow-up period, diabetes changed into an impartial predictor of TLF and TLR however now no longer of MACE.

Limitations: First, the long-time period outcomes have been now no longer evaluated because of the dearth of angiographic follow-up for a big percentage of our take a look at populace and the noticeably quick length of the suggested follow-up. Second, we might also additionally have overvalued DCB's effectiveness due to the fact to the tiny length of the vessels we treated, which can have led to a lesser diploma of ischemia symptoms.

REFERENCES

- Benjamin, B. K., Lu, W., Han, Z., Pan, L., Wang, X., Qin, X., ... & Qiu, C. (2021). Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease. *Journal of Interventional Cardiology*, 2021.
- Tarantini, G., Masiero, G., Barioli, A., Paradies, V., Vlachojannis, G., Tellaroli, P., ... & Smits, P. (2018). Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. *Catheterization and Cardiovascular Interventions*, 92(2), E115-E124.
- Liu, Y., Zheng, B., Zhang, B., Ndong-Lay, R., Nie, F., Tang, N., ... & Huo, Y. (2022). Five-year comparative study of thin-strut rapamycin-eluting bioabsorbable scaffold with metallic drug-eluting stent in porcine coronary artery. *Frontiers in cardiovascular medicine*, 9.
- Nestelberger, T., & Jeger, R. (2019). Drug-coated balloons for small coronary vessel interventions: a literature review. *Interventional Cardiology Review*, 14(3), 131.
- Tsai, C. H., Yeh, C. F., Meng, S. W., Hung, C. S., Lin, M. S., Huang, C. C., ... & Kao, H. L. (2022). Comparison between drug-coated balloons and drug-eluting stents in very small coronary artery interventions. *Scientific Reports*, 12(1), 1-9.
- Serra A. Value of drug-coated balloons in small-vessel disease: have they come of age? *JACC: Cardiovascular Interventions*. 2018;11(23):2393–2395. doi: 10.1016/j.jcin.2018.10.018.
- Mohiaddin H., Wong T. D. F. K., Burke-Gaffney A., Bogle R. G. Drug-coated balloon-only percutaneous coronary intervention for the treatment of DE Novo coronary artery disease: a systematic review. *Cardiology and Therapy*. 2018;7(2):127–149. doi: 10.1007/s40119-018-0121-2.
- Masiero G., Mojoli M., Ueshima D., Tarantini G. Current concepts on coronary revascularization using BRS in patients with diabetes and small vessels disease. *Journal of Thoracic Disease*. 2017;9(9):S940–S949. doi: 10.21037/jtd.2017.06.36.
- Picard F., Doucet S., Asgar A. W. Contemporary use of drug-coated balloons in coronary artery disease: where are we now? *Archives of Cardiovascular Diseases*. 2017;110(4):259–272. doi: 10.1016/j.acvd.2017.01.005.
- Wang X., Lu W., Wang X., et al. Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis. *The International Journal of Cardiovascular Imaging*. 2020;36(2):171–178. doi: 10.1007/s10554-019-01681-y.
- Benjamin B. K., Qiu C., Han Z., et al. The association between type-2 diabetes duration and major adverse cardiac events after percutaneous coronary intervention. *Journal of Diabetes Research*. 2021;2021:9. doi: 10.1155/2021/7580486.7580486
- Rosenberg M., Waliszewski M., Krackhardt F., et al. Drug coated balloon-only strategy in De Novo lesions of large coronary vessels. *Journal of Interventional Cardiology*. 2019;2019:8. doi: 10.1155/2019/6548696.6548696
- Jeger R. V., Farah A., Ohlow M. A., et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. *Lancet (London, England)*. 2018;392(10150):849–856. doi: 10.1016/S0140-6736(18)31719-7.
- Minacapelli A., Piraino D., Buccheri D., Cortese B. Drug-coated balloons for the treatment of in-stent restenosis in diabetic patients: a review of currently available scientific data: DCB for the treatment of ISR in diabetic patients. *Catheterization and Cardiovascular Interventions*. 2018;92(1):E20–E27. doi: 10.1002/ccd.26957.
- Onishi T., Onishi Y., Kobayashi I., Umezawa S., Niwa A. Drug-coated balloon angioplasty for de novo small vessel disease including chronic total occlusion and bifurcation in real-world clinical

- practice. *Cardiovascular Intervention and Therapeutics* . 2019;34(2):139–148. doi: 10.1007/s12928-018-0534-9.
16. Hicks K. A., Mahaffey K. W., Mehran R., et al. 2017 cardiovascular and stroke endpoint definitions for clinical trials. *Journal of the American College of Cardiology* . 2018;71(9):1021–1034.
 17. Tang Y., Qiao S., Su X., et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease: the restore SVD China randomized trial. *JACC: Cardiovascular Interventions* . 2018;11(23):2381–2392. doi: 10.1016/j.jcin.2018.09.009.
 18. Megaly M., Ali A., Abraham B., et al. Outcomes with drug-coated balloons in percutaneous coronary intervention in diabetic patients. *Cardiovascular Revascularization Medicine* . 2020;21(1):78–85. doi: 10.1016/j.carrev.2019.03.001.
 19. Yerasi C., Case B. C., Forrester B. J., et al. Drug-coated balloon for De Novo coronary artery disease: JACC state-of-the-art review. *Journal of the American College of Cardiology* . 2020;75(9):1061–1073. doi: 10.1016/j.jacc.2019.12.046.
 20. Rosenberg M., Waliszewski M., Chin K., et al. Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: the DCB-only all-comers registry. *Catheterization and Cardiovascular Interventions* . 2019;93(2):181–188. doi: 10.1002/ccd.27724.
 21. Cortese B., Di Palma G., Guimaraes M. G., et al. Drug-coated balloon versus drug-eluting Stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. *JACC: Cardiovascular Interventions* . 2020;13(24):2840–2849. doi: 10.1016/j.jcin.2020.08.035.
 22. Jalaluddin M. Treatment of de novo coronary artery lesions with paclitaxel drug coated balloons (DCB) in diabetic and non-diabetic patients. *European Heart Journal* . 2020;41(2):p. 946. doi: 10.1093/ehjci/ehaa946.1486.
 23. Sánchez J. S., Chiarito M., Cortese B., et al. Drug-coated balloons vs. drug-eluting stents for the treatment of small coronary artery disease: a meta-analysis of randomized trials. *Catheterization and Cardiovascular Interventions* . 2020;98:66–75.
 24. Buchanan K. D., Torguson R., Rogers T., et al. In-stent restenosis of drug-eluting stents compared with a matched group of patients with de novo coronary artery stenosis. *The American Journal of Cardiology* . 2018;121(12):1512–1518. doi: 10.1016/j.amjcard.2018.02.033.
 25. Shlofmitz, E., Torguson, R., Zhang, C., Mintz, G. S., Dheendsa, A., Khalid, N., ... & Waksman, R. (2021). Impact of intravascular ultrasound on Outcomes following Percutaneous coronary intervention for In-stent Restenosis (iOPEN-ISR study). *International Journal of Cardiology*, 340, 17-21.